All In MedTech

Device Trial Radar · NCT06592820

Endoscopic Ultrasound Shear Wave Elastography Study

Endoscopic Ultrasound With Shear Wave Elastography for the Assessment of Liver Disease

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Sep 3, 2025

Primary completion

Nov 28, 2028

Study completion Nov 28, 2028

Sponsor

Lead sponsor
Olympus Corporation of the AmericasPublic (7733.T)
Sponsor type
Industry
First posted
Sep 19, 2024

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study shall be a prospective, multicenter, single arm, consecutive, interventional study conducted in a post-market setting using commercially available devices. Consecutive, eligible patients with clinical suspicion of MASLD or MASH reporting for an endoscopic ultrasound and liver biopsy for evaluation of fibrosis will be enrolled. EUS Shear Wave Elastography and Attenuation Imaging technologies will be compared to liver biopsy and FibroScan results and other non-invasive fibrosis screening modalities . The data collected during this study will be evaluated in accordance with the procedures set forth in the protocol. The main question\[s\] it aims to answer are: * Establish optimal cutoffs for EUS-SWE in reference to liver biopsies staging system for liver fibrosis * Evaluate the diagnostic performance of EUS-SWE compared to FibroScan (VCTE) and to other non-invasive fibrosis screening modalities (screening scores). Participants will undergo: * Endoscopic Ultrasound with Shear Wave Elastography (SWE) and Attenuation Imaging (ATI) * Liver biopsy * FibroScan

Conditions

  • MASLD
  • MASH
  • Fibrosis, Liver
  • Chronic Liver Disease

Interventions

  • Endoscopic Ultrasound Shear Wave Elastography (EUS) and Attenuation ImagingDevice

    EUS combines ultrasound technology with endoscopy to gain an internal vantage point to obtain higher resolution ultrasound images. Shear Wave is a software option on the ultrasound system EUS that provides an advanced measure and dynamic display of tissue stiffness which is being evaluated for use in assessing liver fibrosis. Attenuation Imaging (ATI) is a novel application that provides the capability to quantify and color-code the changes in attenuation coefficient of the liver that may arise with changes in liver composition (e.g., increased fat levels).

  • FibroScanDevice

    A small ultrasound probe to measure the velocity of a sound wave passing through the liver. This is converted into kilopascals (kPa), which is used to assess liver fibrosis.

  • Liver biopsyDevice

    A biopsy of liver tissue could be obtained under endoscopic ultrasound guidance, interventional radiology (percutaneously), or surgically. Endoscopic Ultrasound-guided liver biopsy provides high resolution images of left lobe of the liver and a good portion of the right lobe of the liver. This, coupled with Doppler capability, allows the physician to direct the biopsy needle safely into the liver for sampling under real time image guidance.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Shear Wave Elastography (SWE) vs liver biopsy METAVIR staging systemTime frame: During study data analysis

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Hoag Memorial Hospital

    Newport Beach, California · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • Geisinger Medical Center

    Danville, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.